558 related articles for article (PubMed ID: 30502762)
1. The CXCL12 (SDF-1)/CXCR4 chemokine axis: Oncogenic properties, molecular targeting, and synthetic and natural product CXCR4 inhibitors for cancer therapy.
Zhou Y; Cao HB; Li WJ; Zhao L
Chin J Nat Med; 2018 Nov; 16(11):801-810. PubMed ID: 30502762
[TBL] [Abstract][Full Text] [Related]
2. Molecular Pathways: Targeting the CXCR4-CXCL12 Axis--Untapped Potential in the Tumor Microenvironment.
Scala S
Clin Cancer Res; 2015 Oct; 21(19):4278-85. PubMed ID: 26199389
[TBL] [Abstract][Full Text] [Related]
3. Biological/pathological functions of the CXCL12/CXCR4/CXCR7 axes in the pathogenesis of bladder cancer.
Nazari A; Khorramdelazad H; Hassanshahi G
Int J Clin Oncol; 2017 Dec; 22(6):991-1000. PubMed ID: 29022185
[TBL] [Abstract][Full Text] [Related]
4. Targeting CXCL12/CXCR4 Axis in Tumor Immunotherapy.
Zhou W; Guo S; Liu M; Burow ME; Wang G
Curr Med Chem; 2019; 26(17):3026-3041. PubMed ID: 28875842
[TBL] [Abstract][Full Text] [Related]
5. CXCL12-CXCR4/CXCR7 Axis in Colorectal Cancer: Therapeutic Target in Preclinical and Clinical Studies.
Khare T; Bissonnette M; Khare S
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34298991
[TBL] [Abstract][Full Text] [Related]
6. The chemokine receptors CXCR4/CXCR7 and their primary heterodimeric ligands CXCL12 and CXCL12/high mobility group box 1 in pancreatic cancer growth and development: finding flow.
Shakir M; Tang D; Zeh HJ; Tang SW; Anderson CJ; Bahary N; Lotze MT
Pancreas; 2015 May; 44(4):528-34. PubMed ID: 25872129
[TBL] [Abstract][Full Text] [Related]
7. CXCL12 (SDF-1)/CXCR4 pathway in cancer.
Teicher BA; Fricker SP
Clin Cancer Res; 2010 Jun; 16(11):2927-31. PubMed ID: 20484021
[TBL] [Abstract][Full Text] [Related]
8. Stromal cell-derived factor-1 (SDF-1) as a target in liver diseases.
Liepelt A; Tacke F
Am J Physiol Gastrointest Liver Physiol; 2016 Aug; 311(2):G203-9. PubMed ID: 27313175
[TBL] [Abstract][Full Text] [Related]
9. Drug Design Targeting the CXCR4/CXCR7/CXCL12 Pathway.
Xu D; Li R; Wu J; Jiang L; Zhong HA
Curr Top Med Chem; 2016; 16(13):1441-51. PubMed ID: 26369824
[TBL] [Abstract][Full Text] [Related]
10. The CXCR4/SDF-1 chemokine axis: a potential therapeutic target for bone metastases?
Hirbe AC; Morgan EA; Weilbaecher KN
Curr Pharm Des; 2010; 16(11):1284-90. PubMed ID: 20166978
[TBL] [Abstract][Full Text] [Related]
11. Oncogenic roles and drug target of CXCR4/CXCL12 axis in lung cancer and cancer stem cell.
Wang Z; Sun J; Feng Y; Tian X; Wang B; Zhou Y
Tumour Biol; 2016 Jul; 37(7):8515-28. PubMed ID: 27079871
[TBL] [Abstract][Full Text] [Related]
12. CXC chemokine receptor 4 (CXCR4) blockade in cancer treatment.
Bao S; Darvishi M; H Amin A; Al-Haideri MT; Patra I; Kashikova K; Ahmad I; Alsaikhan F; Al-Qaim ZH; Al-Gazally ME; Kiasari BA; Tavakoli-Far B; Sidikov AA; Mustafa YF; Akhavan-Sigari R
J Cancer Res Clin Oncol; 2023 Aug; 149(10):7945-7968. PubMed ID: 36905421
[TBL] [Abstract][Full Text] [Related]
13. CXCL12/CXCR4 signal transduction in diseases and its molecular approaches in targeted-therapy.
Mousavi A
Immunol Lett; 2020 Jan; 217():91-115. PubMed ID: 31747563
[TBL] [Abstract][Full Text] [Related]
14. Chemokine receptor CXCR4: role in gastrointestinal cancer.
Lombardi L; Tavano F; Morelli F; Latiano TP; Di Sebastiano P; Maiello E
Crit Rev Oncol Hematol; 2013 Dec; 88(3):696-705. PubMed ID: 24120239
[TBL] [Abstract][Full Text] [Related]
15. Proinflammatory CXCL12-CXCR4/CXCR7 Signaling Axis Drives Myc-Induced Prostate Cancer in Obese Mice.
Saha A; Ahn S; Blando J; Su F; Kolonin MG; DiGiovanni J
Cancer Res; 2017 Sep; 77(18):5158-5168. PubMed ID: 28687617
[TBL] [Abstract][Full Text] [Related]
16. The good and bad faces of the CXCR4 chemokine receptor.
Teixidó J; Martínez-Moreno M; Díaz-Martínez M; Sevilla-Movilla S
Int J Biochem Cell Biol; 2018 Feb; 95():121-131. PubMed ID: 29288743
[TBL] [Abstract][Full Text] [Related]
17. Drug design strategies focusing on the CXCR4/CXCR7/CXCL12 pathway in leukemia and lymphoma.
Barbieri F; Bajetto A; Thellung S; Würth R; Florio T
Expert Opin Drug Discov; 2016 Nov; 11(11):1093-1109. PubMed ID: 27598329
[TBL] [Abstract][Full Text] [Related]
18. CXCL12 / CXCR4 / CXCR7 chemokine axis and cancer progression.
Sun X; Cheng G; Hao M; Zheng J; Zhou X; Zhang J; Taichman RS; Pienta KJ; Wang J
Cancer Metastasis Rev; 2010 Dec; 29(4):709-22. PubMed ID: 20839032
[TBL] [Abstract][Full Text] [Related]
19. Relevance of the CXCR4/CXCR7-CXCL12 axis and its effect in pathophysiological conditions.
Huynh C; Dingemanse J; Meyer Zu Schwabedissen HE; Sidharta PN
Pharmacol Res; 2020 Nov; 161():105092. PubMed ID: 32758634
[TBL] [Abstract][Full Text] [Related]
20. Potential of CXCR4 antagonists for the treatment of metastatic lung cancer.
Burger JA; Stewart DJ; Wald O; Peled A
Expert Rev Anticancer Ther; 2011 Apr; 11(4):621-30. PubMed ID: 21504328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]